



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Metyrapone (Standard)

Cat. No.:	HY-B1232R
CAS No.:	54-36-4
Molecular Formula:	C ₁₄ H ₁₄ N ₂ O
Molecular Weight:	226.27
Target:	Cytochrome P450; Autophagy; Endogenous Metabolite
Pathway:	Metabolic Enzyme/Protease; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Metyrapone (Standard) is the analytical standard of Metyrapone. This product is intended for research and analytical applications. Metyrapone (Su-4885) is a potent and orally active 11 β -hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with <i>Pseudomonas putida</i> cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression ^{[1][2][3][4][5]} .
IC₅₀ & Target	11 β -hydroxylase, Aldosterone, CYP450, Autophagy ^{[1][4][5]}

REFERENCES

- [1]. Roozendaal B, et al. Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotion and memory. *Psychoneuroendocrinology*. 1996 Nov;21(8):681-93.
- [2]. Jahn H, et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. *Arch Gen Psychiatry*. 2004 Dec;61(12):1235-44.
- [3]. Daniel E, et al. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. *J Clin Endocrinol Metab*. 2015 Nov;100(11):4146-54.
- [4]. Peterson JA, Ullrich V, Hildebrandt AG. Metyrapone interaction with *Pseudomonas putida* cytochrome P-405. *Arch Biochem Biophys*. 1971 Aug;145(2):531-42.
- [5]. Holczer M, et al. A Comprehensive Systems Biological Study of Autophagy-Apoptosis Crosstalk during Endoplasmic Reticulum Stress. *Biomed Res Int*. 2015;2015:319589.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA